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Abstract
Cryptococcal meningoencephalitis (CM) remains the most prevalent invasive fungal infec-
tion worldwide. The main objective of this study was to describe the prevalence of CM and
cryptococcal infection in HIV-infected patients in Madagascar. The secondary objectives
were to assess the adjusted prevalence of CM according to clinical presentation and patient
characteristics, to determine crude 90-day survival according to cryptococcal antigen
(CrAg) status and CM, and to identify the genotypes of Cryptococcus clinical isolates. This
cross-sectional study was carried out at two urban hospitals in Antananarivo (central high-
lands) and Toamasina (east coast) between November 2014 and December 2016. Conse-
cutive HIV-infected adults presenting with CD4 cell counts�200/μl were enrolled. Lateral
flow immunoassays of CrAg were performed on serum for all patients, and on cerebrospinal
fluid for patients with CM symptoms. MALDI-ToF MS, ITS sequencing, and determinations
of the molecular and mating types of the isolates were performed. Fluconazole is the only
drug for CM treatment available in Madagascar. Patients were treated orally, with high
doses (1200 mg/day) for 10–12 weeks and then with 200 mg/day. Minimum inhibitory con-
centrations were determined for amphotericin B, flucytosine, voriconazole and fluconazole
in E-tests. Overall prevalence was 13.2% (95% CI 7.9–20.3) for cryptococcal infection and
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10.9% (95% CI 6.1–17.5) for CM, among the 129 HIV-infected patients studied. The 90-day
mortality rate was 58.8% (10/17) in CrAg-positive patients and 17.9% (20/112) in CrAg-neg-
ative patients (p<0.001). The 13 Cryptococcus strains obtained at baseline were all Crypto-
coccus neoformans var. grubii, genotypes VNI-αA (3 isolates), VNII-αA (4 isolates) or hybrid
VNI/VNII-αAAα (6 isolates), suggesting high diversity. Two strains acquired fluconazole
resistance after four and five months of exposure, respectively. The prevalence of crypto-
coccosis is high in Madagascar and this serious condition is life-threatening in HIV-infected
patients. These findings will be used to raise the awareness of national authorities to
strengthen the national HIV/AIDS control program.
Author summary
Cryptococcal meningoencephalitis (CM) remains the most prevalent invasive fungal
infection worldwide, with an estimated mortality of 70% in sub-Saharan Africa. In this
cross-sectional study, we investigated the prevalence, clinical features, case-management
and outcome of CM in HIV-infected patients. We also molecularly characterized the
Cryptococcus isolates from these patients. The study was conducted in the main hospitals
of two geographically distant cities, one located at Antananarivo in the central highlands
and the other at Toamasina on the east coast. The prevalence of cryptococcal infection
was higher than previously reported global prevalence values, and most of the patients
developed CM. Classical signs of meningoencephalitis, including headache, fever and
neck pain, were observed, as reported in previous studies. Ninety-day mortality (58.8%)
was higher in patients with Cryptococcus infections than in non-infected patients (17.9%).
All patients diagnosed with infection were treated with high-dose fluconazole, the only
treatment available in Madagascar, in accordance with WHO recommendations. Molecu-
lar analyses of isolates from both regions revealed high levels of genome diversity and sug-
gested that further environmental and larger clinical studies would be worthwhile. In
conclusion, the prevalence of cryptococcal diseases is high in Madagascar, which is cur-
rently faced with the challenges of prioritizing various diseases of public health concern,
providing health centers with rapid diagnostic tools and facilitating access to more reliable
molecules.
Introduction
Cryptococcal meningoencephalitis (CM) is a common opportunistic infection in developing
countries, including those of sub-Saharan Africa. It mostly affects severely immunocompro-
mised HIV-infected patients. With an estimated 625,000 deaths annually [1] and a global bur-
den of almost a million cases per year [2], cryptococcal infection is one of the most devastating
infectious diseases in sub-Saharan Africa and worldwide. A recent update of the global burden
of HIV-associated cryptococcal meningoencephalitis (CM) reported an annual incidence of
162,500 cases in sub-Saharan Africa, accounting for 73% of the estimated number of cases
globally and 135,500 deaths [3].
Most cryptococcal infections in HIV-infected patients are caused by the Cryptococcus neo-
formans (Cn) species complex, which includes two varieties and five molecular types: VNI,
VNII and VNB (Cn var. grubii serotype A), VNIV (Cn var. neoformans serotype D), and
VNIII, corresponding to intervarietal hybrids [4,5]. A recent taxonomic revision has also been
Cryptococcal meningoencephalitis in HIV-infected patients in Madagascar
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proposed, in which Cn var. neoformans and Cn var. grubii are considered to be separate species
[6]. VNI is the most prevalent molecular type of the Cn species complex worldwide; it is found
in diverse environments, including bird guano, decaying wood, trees and soil [7], and can be
transmitted to humans by basidiospore or small-sized blastospores inhalation, leading to pri-
mary lung colonization. Central nervous system invasion occurs principally in immunocom-
promised individuals, including people living with HIV [8], and results in CM, the most
common and severe clinical form of cryptococcal infection [9].
The recent development of antigenic and molecular techniques has greatly improved the
diagnosis of cryptococcal infection. The lateral flow immunoassay (LFA) has proved to be a
sensitive point-of-care test capable of detecting the cryptococcal antigen (CrAg) rapidly, which
should make it possible to implement treatment early, to reduce mortality [10].
With the spread of antiretroviral therapy (ART) in developed countries, the incidence of
cryptococcal infection has greatly decreased. In developing countries, where access to ART is
more limited, HIV infection remains the main risk factor for CM [11] and the case-fatality rate
associated with CM can reach up to 70% in sub-Saharan Africa [1]. Little is known about the
epidemiology, prevalence, associated clinical features and population diversity of the Crypto-
coccus species complex in Madagascar, in a context of low HIV/AIDS prevalence [12].
The main objective of this study was to evaluate the prevalence of CM and cryptococcal
infection in HIV-infected patients. The secondary objectives were to assess the CM prevalence
adjusted for clinical presentation and patient characteristics, to determine crude 90-day sur-
vival according to CrAg status and CM, and the genotypes of clinical isolates of Cryptococcus.
Materials and methods
Study design and population
This cross-sectional study was conducted at two urban hospitals: the Infectious Diseases
department of Befelatanana University Hospital, Antananarivo, in the central highlands, and
the Pneumology department of the University Hospital Analakininina, Toamasina, on the east
coast. Consecutive HIV-infected adults presenting with CD4 cell counts� 200/μl were
enrolled between November 2014 and December 2016. As the primary objective was descrip-
tive (i.e. estimation of the prevalence of cryptococcal meningoencephalitis in HIV positive
individuals) and no previous data was available, we did not calculate sample size. Indeed, our
cross-sectional study is the first estimate of the prevalence in Madagascar. Based on our result,
with a sample size of 129 patients and the observed prevalence, the precision of the prevalence
was lower than +/-7%. Study participants were not required to be ART naïve. Patients with a
known history of cryptococcal disease were excluded from the study. A standardized case
record form detailing sociodemographic characteristics, clinical signs and symptoms, was
completed for each individual. The WHO recommends a one-week short-course induction
regimen including amphotericin B deoxycholate (1 mg/kg/day) and flucytosine (100 mg/kg/
day), followed by 1200 mg/day fluconazole for one week and then 800 mg/day fluconazole for
eight weeks as a consolidation regimen, for the treatment of immunocompromised patients
with CM [15]. However, amphotericin B and flucytosine are unavailable in Madagascar.
Patients therefore received high-dose oral fluconazole alone (at least 1200 mg/day) for 10–12
weeks, followed by maintenance therapy with 200 mg/day fluconazole.
Ethics approval for the study was obtained from the National Ethics Committee of the Min-
istry of Health of Madagascar (authorization 111-MSANP/CE, dated 03/11/2014). Written
informed consent was provided individually by all study participants, or by the close relatives
of unconscious patients.
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Sample collection and laboratory testing
CD4 cell counts were determined with blood samples collected during routine immunological
testing before the enrolment of the patient in the study. If CD4 cell count was below 200 cells/
μl, the corresponding serum was tested for the presence of CrAg, by LFA, performed according
to the manufacturer’s instructions (IMMY, Oklahoma, USA) [13]. If a positive result was
obtained, the patient was hospitalized, and a detailed interview and clinical examination were
performed to check for signs of meningoencephalitis (e.g., headache, meningism, fever, photo-
phobia, or altered mental status). Patients with negative LFA results attended a check-up visit
after six months. If meningoencephalitis was clinically suspected, lumbar puncture was per-
formed to check for the presence of CrAg in the cerebrospinal fluid (CSF). CSF pressure was
measured manually in a sterilized tube. For cases of confirmed infection, CrAg was quantified
in CSF specimens at an initial dilution of 1:5, and then in two-fold serial dilutions to 1:1280,
and a direct microscopic examination was performed after staining of the sample with India
ink. HIV-1 RNA viral load (HIV VL) was quantified in plasma samples from study participants
with the Generic HIV Viral Load assay (Biocentric, Bandol, France), as previously described
[14]. The threshold for detection of this assay was 250 copies/ml (2.4 log10 copies/ml).
Other opportunistic infections were diagnosed based on clinical findings (consistent clini-
cal presentation, duration of symptoms and therapeutic response to specific treatment), radio-
logical findings, CD4 cells count, histological findings and confirmatory biological tests.
Mycological and molecular analyses
Sabouraud dextrose agar (Biokar Diagnostics, Beauvais, France) tubes supplemented with
chloramphenicol were inoculated with CSF samples from patients with clinically suspected
CM, incubated at 30˚C, and examined every two days. Genomic DNA was extracted with the
GenElute Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich), and the internal tran-
scribed spacers (ITS) region, including the 5.8S rRNA gene (514 bp), was sequenced as previ-
ously described [15]. The sequences were assembled and compared with sequences present in
the International Society for Human and Animal Mycology (ISHAM) ITS Database [16]. The
fungal isolates were then sent to Grenoble Alpes University Hospital in France for matrix-
assisted laser desorption ionization time-of-flight (MALDI-ToF) mass spectrometry with a
Bruker BioTyper instrument [17], and to Università degli Studi di Milano in Italy for addi-
tional molecular analyses. We determined the molecular and mating types allele patterns of
the isolates, by performing two specific multiplex PCRs, as described elsewhere [18–20].
Strains H99 (VNI-αA), IUM 96–2828 (VNI-aA), WM626 (VNII-αA), JEC21 (VNIV-αD),
JEC20 (VNIV-aD), and CBS132 (VNIII-αADa) were used as reference strains. The minimum
inhibitory concentrations (MIC) for amphotericin B, flucytosine, voriconazole and fluconazole
was determined with E-tests (Biome´rieux, La Balme les Grottes, France), according to the
manufacturer’s instructions. The MIC was determined after 72 h of incubation at 35˚C on
solid RPMI medium. In the absence of clinical breakpoints for the Cryptococcus species com-
plex, we used the epidemiological cutoff values (ECV) established in previous studies [21,22].
Clinical Breakpoints are defined on the basis of five parameters: antifungal dose regimens,
MIC distributions from multiple laboratories, ECV, pharmacokinetic/pharmacodynamics
parameters and clinical outcome of multiple patients. ECV are defined with respect to the
higher MIC of wild-type isolates.
Statistical analysis
Categorical variables are expressed as numbers and percentages, with 95% confidence intervals
(CI); continuous covariates are expressed as the median and interquartile range (IQR). Chi2
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tests or Fisher’s exact tests were used to compare categorical variables. Continuous covariates
were compared in Mann–Whitney U-tests or Kruskal–Wallis one-way analysis of variance.
Univariate and multivariate Poisson regression analysis was performed, with robust modeling
of variance error, to estimate the crude and adjusted prevalence ratios (PRs) of CM as a func-
tion of the principal characteristics of the patients. Patients without CM were used as the refer-
ence group. We preferred this type of modeling over logistic regression for the estimation of
PRs [23]. Factors associated with patient survival were assessed with Kaplan–Meier curves and
compared in log-rank tests. Follow-up and vital status recording were censored at 90 days after
study enrolment for this analysis. Statistical analyses were performed with Epi Info 7.1.3 (Cen-
ters for Disease Control and Prevention, Atlanta, Georgia) and Stata 11.0 (StataCorp). All tests
were two-tailed and a p-value of less than 0.05 was considered significant.
Results
Characteristics of the study population
In total, 129 HIV-infected patients were enrolled in this study (Table 1). The median age of par-
ticipants was 37 years (IQR 32.0–45.0), and 62.0% were male. The median body mass index
(BMI) was 17.6 kg/m2 (IQR 15.8–20.0). No differences were noted in age, sex or BMI between
the 17 CrAg-positive (CrAg+) patients and the 112 CrAg-negative (CrAg-) patients. Overall,
58.9% of patients were inpatients, with a median duration of hospitalization of 22 days (IQR
11.0–35.0), and only 38.1% were prescribed ART. In total, 24.0% and 59.2% of the patients pre-
sented with disease at WHO clinical stages 3 and 4, respectively; the median baseline CD4 cell
count was 83 cells/μl (IQR 31.5–123.5), and 62.8% of patients had a CD4 cell count<100 cells/
μl. The study participants included 88.1% with an HIV VL>250 copies/ml, the median HIV
VL being 5.6 log10/ml (IQR 4.4–6.5). HIV VL did not differ significantly between CrAg
+ and
CrAg- patients. Most patients (81.4%) had only recently been diagnosed with HIV infection.
CrAg+ patients were more likely than CrAg- patients to present low CD4 cell counts (p = 0.018).
Prevalence of cryptococcal infection and cryptococcal meningoencephalitis
Seventeen of the 129 HIV-infected patients enrolled had detectable CrAg in the blood; 14 of
these patients also had CrAg in CSF and 13 had positive results for Cryptococcus spp. culture
from CSF. The overall prevalence of cryptococcal infection was 13.2% (17/129, 95% CI 7.9–
20.3), and that of CM was 10.9% (14/129, 95% CI 6.1–17.5). The 20.0% prevalence reported at
the Toamasina site (6/30, 95% CI 7.7–38.6) was not significantly different from the 11.1% prev-
alence at Antananarivo site (11/99, 95% CI 5.7–19.1) [p = 0.21].
On stratification by CD4 cell count, 16 of the patients with CrAg in serum samples had
CD4 cell counts�100 cells/μl (including the 14 patients with CrAg detection in CSF), whereas
only one patient had a CD4 cell count between 100 and 200 cells/μl (p = 0.0029). Ten of the 14
CSF CrAg+ patients, 10 (71.4%) were severely immunocompromised, with CD4 cell counts
<50 cells/μl (range: 4 to 44).
Clinical features
At baseline, CrAg+ patients presented more frequently than CrAg- patients with headache
(p<0.001), neck pain (p<0.001), photophobia (p = 0.004), and hearing disorders (p = 0.017)
(Table 1). On physical examination, CrAg+ patients had a higher prevalence of meningeal
signs (neck stiffness, p<0.001; Kernig’s sign, p = 0.005; and Brudzinski’s sign, p = 0.002) than
CrAg- patients. Amongst those with CM, there were 4 patients in whom ART was started
before the diagnosis of CM (from 2 to 891 days). However, 2 of them have likely experienced a
Cryptococcal meningoencephalitis in HIV-infected patients in Madagascar
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Table 1. Descriptive analysis and characteristics of the HIV-infected patients at first visit with CD4� 200 cells/μl, Madagascar, 2014–2016.
Variable Total Antigenemia negative Antigenemia positive p
No. patients 129 112 17
Sex, n (%)
- Male 80 (62.0) 70 (62.5) 10 (58.8) 0.771
- Female 49 (38.0) 42 (37.5) 7 (41.2)
Age, years, median (IQR) 37.0 (32–45) 37.0 (32–45) 37.0 (34–49) 0.531
BMI, kg/m2, median (IQR) 17.6 (15.8–20.0) 18.0 (16.0–20.3) 16.7 (12.8–18.0) 0.169
CD4 cell count, /μl, median (IQR) 83 (31.5–123.5) 86 (35–146) 38 (20–89) 0.018
CD4 cell count per μl, n (%)
- < 100 81 (62.8) 65 (58.0) 16 (94.1) 0.017
- 100–200 48 (37.2) 47 (42.0) 1 (5.9)
Median HIV-1 RNA, log10/ml (IQR), n = 126 5.6 (4.4–6.5) 5.5 (4.3–6.4) 6.0 (5.3–6.7) 0.085
HIV-1 VL interpretation, (%)
- Detectable 111/126 (88.1) 96/110 (87.3) 15/16 (93.8) 0.454
- Undetectable 15/126 (11.9) 14/110 (12.7) 1/16 (6.3)
WHO stage at enrolment, (%)
- 1 10/125 (8.0) 10/108 (9.3) 0 0.242
- 2 11/125 (8.8) 10/108 (9.3) 1/17 (5.9)
- 3 30/125 (24.0) 28/108 (25.9) 2/17 (11.8)
- 4 74/125 (59.2) 60/108 (55.6) 14/17 (82.4)
ART at baseline, n (%)
- Yes 48/126 (38.1) 43/109 (39.4) 5/17 (29.4) 0.428
- No 78/126 (61.9) 66/109 (60.6) 12/17 (70.6)
Hospitalization 76/129 (58.9) 63/112 (56.3) 13/17 (76.5) 0.114
Hospital stay, days, median (IQR) 22 (11.0–35.0) 23.0 (11.0–33.0) 21.0 (10.0–43.0) 0.923
Newly detected cases, n (%) 105/129 (81.4) 91/112 (81.3) 14/17 (82.4) 1.000
Manifestations, n (%)
- Headache 44/125 (35.2) 29/108 (26.9) 15/17 (88.2) <0.001
- Fever 88/127 (69.3) 74/110 (67.3) 14/17 (82.4) 0.21
- Neck pain 27/126 (21.4) 15/109 (13.8) 12/17 (70.6) <0.001
- Night sweats 58/125 (46.4) 47/109 (43.1) 11/16 (68.8) 0.055
- Cough 78/128 (60.9) 68/111 (61.3) 10/17 (58.8) 0.848
- Photophobia 15/124 (12.1) 9/108 (8.3) 6/16 (37.5) 0.004
- Hearing disorders 13/125 (10.4) 8/108 (7.4) 5/17 (29.4) 0.017
- Blurred vision 20/124 (16.1) 17/108 (15.7) 3/16 (18.8) 0.722
Symptoms, n (%)
- Temperature �38.0˚C
- Neck stiffness
43/126 (34.1)
16/126 (12.7)
35/109 (32.1)
8/109 (7.3)
8/17 (47.1)
8/17 (47.1)
0.751
<0.001
- Confusion 25/126 (19.8) 20/109 (24.5) 5/17 (29.4) 0.328
- Seizures 11/127 (8.7) 8/102 (7.3) 3/17 (17.7) 0.166
- Kernig’s sign 7/126 (5.6) 3/107 (2.7) 4/16 (25.0) 0.005
- Brudzinski’s sign 6/124 (4.8) 2/108 (1.9) 4/16 (25.0) 0.002
- Altered mental status 17/124 (13.7) 15/107 (14.0) 2/17 (11.8) 1
- Neurological deficit 14/127 (11.0) 14/110 (12.7) 0 0.213
Opportunistic infections, n (%) 67/104 (64.4) 61/92 (66.3) 6/12 (50.0) 0.339
- Pneumocystis pneumonia 47/103 (45.6) 41/91 (45.1) 6/17 (35.3) 0.746
- Tuberculosis 37/103 (35.9) 34/91 (37.4) 3/12 (25.0) 0.53
- Cerebral toxoplasmosis 15/103 (14.6) 12/91 (13.2) 3/12 (25.0) 0.376
- Kaposi’s sarcoma 5/104 (4.8) 5/92 (5.4) 0 1
- Other 12/104 (11.5) 11/92 (12.0) 1/12 (8.3) 1
(Continued)
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discontinuation of ART as their HIV viral load were detectable at inclusion. One patient has
been prescribed ART 2 days before the diagnosis of CM and one patient, has been prescribed
ART more than 2 years before the diagnosis of CM.
The following characteristics were associated with CM in robust univariate Poisson regres-
sion analysis: ART (crude prevalence ratio [cPR] = 0.3, 95% CI: 0.1–0.8), WHO category (cPR
non estimable, p<0.001), CD4 cell count<100 cells/μl (cPR = 8.0, 95% CI: 1.1–59.5), neck
pain (cPR = 22, 95% CI: 5.2–92.9), headache (cPR non estimable, p<0.001), hearing disorders
(cPR = 3.4, 95% CI: 1.3–9.5), photophobia (cPR = 6.2, 95% CI: 2.4–16.1), night sweats (cPR =
4.9, 95% CI: 1.1–13.4), stiff neck (cPR = 6.9, 95% CI: 2.8–17.1), Kernig’s sign (cPR = 6.8, 95%
CI: 2.8–16.3), Brudzinski’s sign (cPR = 7.9, 95% CI: 3.4–17.9), current shingles (cPR non esti-
mable, p<0.001) and Kaposi’s sarcoma (cPR non estimable p<0.001). ART (adjusted preva-
lence ratio [PR] = 0.4, 95% CI: 0.2–0.9) and the presence of neck pain (adjusted PR = 15.7,
95% CI: 3.4–72.1) remained independently associated with CM after multivariate Poisson
regression analysis adjusted for CD4 cell count.
CSF opening pressure data were available for seven of the 14 patients in whom CrAg was
detected in the CSF; this pressure was high (>20 cm H2O) in three of these seven patients
(42.9%; data not shown).
Clinical outcome and analysis of risk factors
The 129 patients were hospitalized for 3648 patient-days in total, with 30 patients (23.3%) dying
within 90 days. Amongst the 14 patients with CM, there were 9 deaths during the follow-up
including 8 deaths occurring within 90 days. The outcome for one patient (CRY130) was
unknown because he was lost to follow-up (Table 2). The 90-day mortality rate was 58.8% (10/
17) for CrAg+ patients and 17.9% (20/112) for CrAg- patients (p<0.001). Kaplan-Meier survival
curves were plotted after stratification for CrAg status (Fig 1; p = 0.096, log-rank test). Survival
at 30, 60 and 90 days was 75% (95% CI 61–84%), 65% (50–76%) and 62% (46–74%), respec-
tively, for CrAg- patients; and 59% (32–78%), 59% (32–78%), and 35% (12–59%), respectively,
for CrAg+ patients. The 90-day mortality rate was 57.1% (8/14) in patients with CM and 19.1%
(22/115) in patients without CM (p = 0.004). Survival at 30 days, 60 days and 90 days was 73%
(95% CI 60–82%), 64% (49–75%) and 61% (46–73%), respectively, for patients without CM;
and 64% (34–83%), 64% (34–83%), and 34% (10–61%), respectively, for patients with CM.
CrAg titration and culture of serial lumbar puncture specimens during
treatment
Fourteen of the 17 CSF samples processed at baseline tested positive for CrAg and for India
ink staining, with 100% concordance between the results obtained with these techniques
Table 1. (Continued)
Variable Total Antigenemia negative Antigenemia positive p
No. patients 129 112 17
Non OIs, n (%) 41/103 (39.8) 35/91 (38.5) 6/12 (50.0) 0.535
- Candidiasis 31/103 (30.1) 26/91 (28.6) 5/12 (41.7) 0.504
- Herpes 5/103 (4.9) 4/91 (4.4) 1/12 (8.3) 0.469
- Herpes zoster 4/103 (3.9) 4/91 (4.4) 0/12 (0) 1
- Pulmonary infection 11/103 (10.7) 10/91 (11.0) 1/12 (8.3) 1
OI: opportunistic infection IQR: interquartile range; VL: viral load; p: probability value
https://doi.org/10.1371/journal.pntd.0007984.t001
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Table 2. Changes in cryptococcal antigen titers and viable yeasts in the CSF of the 14 patients with cryptococcal meningitis.
Case ID CrAg titer Culture Outcome
Day 1 Day 15/29 Day 30/59 Day 60/79 Day 90/120
CRY017 �1:1280 pos day 1 dead day 4
CRY033 1:20 1:10 neg day 11 dead day 69
CRY041 1:640 1:320 1:320 1:160 1:40 neg day 104 dead day 141
CRY061 �1:1280 pos day 1 dead day 12
CRY067 1:320 1:640 1:40 1:40 neg day 39 dead day 68
CRY069 �1:1280 1:1280 1:40 1:40 neg day 28 alive day 197
CRY070 �1:1280 �1:1280 �1:1280 �1:1280 pos day 56 dead day 73
CRY094 �1:1280 pos day 1 dead day 19
CRY101 �1:1280 pos day 1 dead day 4
CRY112 1:640 1:320 1:160 1:160 neg day 122 alive day 160
CRY114 �1:1280 pos day 1 dead day 12
CRY124 1:320 na alive day 120
CRY128 �1:1280 1:80 1:40 1:40 1:40 neg day 77 alive day 120
CRY130 1:1280 pos day 1 lost to follow-up
na, not applicable (insufficient quantity)
Note: all patients were treated with fluconazole, except for patient CRY128, who received amphotericin B and high-dose fluconazole
https://doi.org/10.1371/journal.pntd.0007984.t002
Fig 1. Kaplan-Meier survival curves for patients positive and negative for CrAg in tests on serum.
https://doi.org/10.1371/journal.pntd.0007984.g001
Cryptococcal meningoencephalitis in HIV-infected patients in Madagascar
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007984 January 13, 2020 8 / 14
(Table 2). In one case (CRY08124), too little CSF was available for culture. Yeasts grew from
the remaining 13 samples on Sabouraud-chloramphenicol media, and the CrAg LFA test con-
firmed the diagnosis of CM in these cases.
CrAg titration results for the CSF are shown in Table 2. At baseline, nine patients had very
high titers (�1:1280), four had high titers (1:320–640), and one had a low titer (1:20). On fol-
low-up, six patients with very high titers (�1:1280) underwent only one CrAg titer determina-
tion due to premature death (CRY017, -061, 094, -101 and -114) or loss to follow-up
(CRY130). One patient (CRY124) with a high titer (1:320) was not monitored but was reported
to be alive 120 days post-treatment.
In the remaining seven patients, the clearance of viable yeasts was observed relatively early,
at day 11, in one case (CRY033), and late (days 28 to 122) for the other six cases (CRY041,
-067, -069, -070, -112 and -128), even on high-dose fluconazole. Fungal load remained persis-
tently high in the CRY070 isolate. These finding suggest that the infection clearance rate is
low.
Culture and India ink staining were systematically performed to assess the clearance of via-
ble yeasts during patient monitoring. In total, 17 isolates were retrieved from the 13 patients
for molecular analyses.
Molecular identification and typing
All 17 clinical isolates obtained from CSF cultures (13 at baseline and 4 during follow-up) were
identified as Cn var. grubii by ITS sequencing and MALDI-ToF mass spectrometry (Table 3).
The 13 initial isolates were genotyped. They belonged to the most widely distributed VNI type
(3 isolates), the rarer but also globally distributed VNII type (4 isolates) and a hybrid intravar-
ietal type VNI/VNII (6 isolates). All three molecular types were found at Antananarivo,
whereas only VNI/VNII was found at Toamasina. The molecular types VNI and VNII were
mating-type αA, and molecular type VNI/VNII was mating-type αAAα.
Antifungal susceptibility
All 17 Cn var. grubii isolates were tested (Table 3). Two isolates (CRY128 and CRY041)
acquired fluconazole resistance after four and five months of exposure, respectively. Surpris-
ingly, the MICs of two isolates from CRY070 case, described earlier and collected almost two
months apart, were within the normal range, as defined by the ECV.
Discussion
A high overall prevalence of CM (10.9%) and cryptococcal infection (13.2%) was found at the
two hospitals located in the central highlands (Antananarivo) and on the east coast (Toama-
sina). The prevalence of cryptococcal infection in Toamasina (20.0%) did not differ signifi-
cantly from that in Antananarivo (11.1%). After stratification by CD4 cell count, most cases of
CrAg+ (94.1%) had <100 cells/μl. These findings are not surprising, because a high prevalence
was expected in inpatients presenting with advanced HIV disease, as in our study, in which
83.2% of patients had reached WHO stage 3–4. By comparison, a mean global prevalence of
cryptococcal infection of 6.0% was reported in outpatients with a CD4 cell count<100/μl
from 29 countries [3]. The high prevalence observed here may also be explained by the small
proportion of patients on ART before the development of CM. The high median viral load (5.6
log10/ml) was associated with a low median CD4 cell count (83 cells/μl), confirming the pres-
ence of advanced immunosuppression.
Immediately after diagnosis, patients with cryptococcal infection and CM were treated with
at least 1200 mg fluconazole daily for at least 10 to 12 weeks, or until CSF cultures gave
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negative results for patients with CM. Outcome was poor in CrAg+ patients, who had a higher
90-day mortality rate (58.8%) than CrAg- patients (17.9%). The causes of death were attributed
to the following factors, either separately or in combination. First, most of the patients (81.4%)
were diagnosed with HIV infection and cryptococcal disease at the same time, and were
already severely immunosuppressed. Second, for the other patients, who received ART, poor
compliance, as revealed by the high rates of virological failure, may have worsened HIV status,
leading to opportunistic infections. Third, monotherapy with fluconazole, which is fungistatic
Table 3. Molecular and mating types, and antifungal susceptibility of Cryptococcus neoformans var. grubii isolated from HIV-infected patients with cryptococcal
meningitis in Madagascar.
Case ID Date of
isolation
Age/
Sex
Location CD4 count
(cell/μl)
MALDI-ToF Molecular
type
Mating
type
Minimum inhibitory concentration (MIC, μg/ml)
AMBa
(ECVe = 1)
5FCb
(ECVe = 16)
VRZc
(ECVe = 0.5)
FLZd
(ECVe = 32)
CRY017 29/01/2015 34/F Antananarivo 4 C. neoformans
var. grubii
VNI αA 0.190 >32 0.047 12.0
CRY033 17/04/2015 50/M Antananarivo 89 C. neoformans
var. grubii
VNII αA 0.250 >32 0.016 1.0
CRY041 07/07/2015 38/M Antananarivo 27 C. neoformans
var. grubii
VNII αA 0.064 6 0.047 12.0
17/07/2015 nd C. neoformans
var. grubii
nd nd 0.047 6 0.047 12.0
04/08/2015 nd C. neoformans
var. grubii
nd nd 0.500 >32 0.500 48.0
CRY061 10/08/2015 29/M Toamasina 16 C. neoformans
var. grubii
VNI/VNII αAAα 0.250 >32 0.032 32.0
CRY067 29/08/2015 35/F Toamasina 20 C. neoformans
var. grubii
VNI/VNII αAAα 0.190 >32 0.094 12.0
CRY069 14/09/2015 42/M Toamasina 38 C. neoformans
var. grubii
VNI/VNII αAAα 0.125 >32 0.004 2.0
CRY070 21/09/2015 60/M Antananarivo 19 C. neoformans
var. grubii
VNI αA 0.125 >32 0.064 12.0
17/11/2015 nd C. neoformans
var. grubii
nd nd 0.500 >32 0.064 12.0
CRY094 11/01/2016 48/M Antananarivo 22 C. neoformans
var. grubii
VNI/VNII αAAα 0.032 8 0.047 12.0
CRY101 07/03/2016 36/F Antananarivo 24 C. neoformans
var. grubii
VNI αA 0.064 4 0.064 8.0
CRY112 10/05/2016 50/M Antananarivo 92 C. neoformans
var. grubii
VNII αA 0.250 4 0.016 2.0
CRY114 10/05/2016 42/F Antananarivo 86 C. neoformans
var. grubii
VNII αA 0.320 >32 0.016 2.0
CRY128 10/10/2016 37/M Antananarivo 19 C. neoformans
var. grubii
VNI/VNII αAAα 0.250 >32 0.064 12.0
01/12/2016 nd C. neoformans
var. grubii
nd nd 0.380 >32 0.064 >256
CRY130 08/12/2016 30/M Toamasina 199 C. neoformans
var. grubii
VNI/VNII αAAα 0.190 >32 0.047 0.5
a AMB, amphotericin B
b 5FC, 5-flucytosine
c VRZ, voriconazole
d FLZ, fluconazole
e ECV, epidemiological cut-off value (μg/ml)
nd, not done
https://doi.org/10.1371/journal.pntd.0007984.t003
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rather than fungicidal, even at high doses, may not be optimal for the induction treatment of
CM or cryptococcal infection [24–26], and should be replaced with the recommended regimen
based on amphotericin or fluconazole combined with flucytosine [27]. Only one patient was
treated with a combination of amphotericin and high-dose fluconazole, and this patient sur-
vived and was discharged.
Confirmatory tests for other opportunistic infections like pneumocystis pneumonia, cere-
bral toxoplasmosis and Kaposi sarcoma have been carried out on case-by-case basis and
depending on whether or not the patient could bear the cost of these tests. Consequently, the
burden of these opportunistic infections, especially pneumocystis pneumonia could potentially
be overestimated. However, the presence of multiple opportunistic infections confirms the
severe immunosuppression amongst these HIV-infected patients and seems to be a common
situation in the study settings. The development of more reliable and convenient diagnostic
tools has improved our knowledge of the infectious disease burden. This study provided us
with an opportunity to set up and demonstrate the utility of the point-of-care CrAg LFA in the
hospitals of Madagascar, as already described [28]. This study also facilitated the implementa-
tion of an open polyvalent platform using the French ANRS generic assay to measure HIV VL
[14]. Our goal was to increase the capacity of the laboratory, and, subsequently, to improve
access to HIV VL determinations in Madagascar. From August 2015 to December 2018,
almost 1,951 HIV VL determinations from 1315 patients were available (Mala Rakoto Andria-
narivelo, personal communication).
This study describes the first molecular characterization of Cn var. grubii isolates in Mada-
gascar and reveals the presence of molecular type VNI, mating type αA (3 isolates), molecular
type VNII mating type αA (4 isolates) and hybrid intravarietal VNI/VNII mating type αAAα
(6 isolates). Molecular type VNI is the most prevalent worldwide, sub-Saharan Africa included
[4]. Molecular type VNII is also widely distributed, but seems to be rare or underestimated
[20]. Clinical and virulent hybrid intravarietal VNI/VNII isolates were isolated in the 1990s in
Australia and Colombia [29], but the distribution of this molecular type remains poorly docu-
mented. In our study, CM associated with these three molecular types occurred in Antanana-
rivo, in the central highlands, whereas only VNI/VNII was detected in the port city of
Toamasina. Our findings suggest that Cn var. grubii displays considerable genetic diversity in
both regions. The major environmental sources of the two varieties of Cn are soil contami-
nated with excreta from pigeons and other birds, and, less frequently, decaying wood and trees
such as Eucalyptus [4,9], which are very common in Madagascar. It would be interesting to
extend the clinical study to other representative regions of Madagascar and to conduct an envi-
ronmental investigation to identify the ecological niche of Cn and to understand its impact on
human populations.
The rapid acquisition of resistance to fluconazole, as observed in two isolates in this study,
provides an additional argument for making amphotericin B and 5-fluorocytosine available.
One of the serious difficulties encountered in the management of patients with cryptococcosis
in Madagascar is the lack of alternatives to fluconazole. The purchase of amphotericin B and
5-fluorocytosine was initially planned, but the restrictive administrative procedures for impor-
tation, including an obligation to order much larger quantities of drugs than were required for
this study, prevented us from making such an order.
In conclusion, this study highlights the high prevalence of cryptococcal infection and CM
in HIV-infected patients with CD4 cell counts < 200/μl. CM is a major killer of HIV-infected
patients in Madagascar. The LFA is a rapid test that is easy to perform and should be made
available in HIV care centers for confirmation of the diagnosis. Monotherapy with oral flucon-
azole and the non-availability of other drugs against cryptococcosis remain crucial issues. The
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conclusions of this study will be used to raise the awareness of national authorities, to reinforce
the national HIV/AIDS control program.
Supporting information
S1 Checklist. Strobe checklist.
(DOCX)
S1 Appendix. De-identified raw data.
(XLSX)
Author Contributions
Conceptualization: Rivonirina Andry Rakotoarivelo, Tahinamandranto Rasamoelina, Muriel
Cornet, Mala Rakoto Andrianarivelo.
Data curation: Rivonirina Andry Rakotoarivelo, Mihaja Raberahona, Tahinamandranto Rasa-
moelina, Thomas Be´net, Philippe Vanhems, Luisa Romanò, Massimo Cogliati, Muriel Cor-
net, Mala Rakoto Andrianarivelo.
Formal analysis: Rivonirina Andry Rakotoarivelo, Mihaja Raberahona, Thomas Be´net, Phi-
lippe Vanhems, Luisa Romanò, Massimo Cogliati, Muriel Cornet, Mala Rakoto
Andrianarivelo.
Funding acquisition: Rivonirina Andry Rakotoarivelo, Mala Rakoto Andrianarivelo.
Investigation: Rivonirina Andry Rakotoarivelo, Mihaja Raberahona, Tahinamandranto Rasa-
moelina, Andriamihaja Rabezanahary, Fetra Angelot Rakotomalala, Tiana Razafinambi-
nintsoa, Thomas Be´net, Luisa Romanò, Massimo Cogliati, Muriel Cornet, Mala Rakoto
Andrianarivelo.
Methodology: Rivonirina Andry Rakotoarivelo, Mihaja Raberahona, Thomas Be´net, Philippe
Vanhems, Mamy Jean de Dieu Randria, Luisa Romanò, Massimo Cogliati, Muriel Cornet,
Mala Rakoto Andrianarivelo.
Resources: Mala Rakoto Andrianarivelo.
Supervision: Rivonirina Andry Rakotoarivelo, Mihaja Raberahona, Muriel Cornet, Mala
Rakoto Andrianarivelo.
Validation: Mihaja Raberahona.
Writing – original draft: Rivonirina Andry Rakotoarivelo, Mihaja Raberahona, Mala Rakoto
Andrianarivelo.
Writing – review & editing: Rivonirina Andry Rakotoarivelo, Mihaja Raberahona, Thomas
Be´net, Philippe Vanhems, Massimo Cogliati, Muriel Cornet, Mala Rakoto Andrianarivelo.
References
1. Park BJ, Wannemuehle KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current
global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009; 23(4):525–
530. https://doi.org/10.1097/QAD.0b013e328322ffac PMID: 19182676
2. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal
infections. Sci Transl Med. 2012; 4(165): 165rv13. https://doi.org/10.1126/scitranslmed.3004404
PMID: 23253612
Cryptococcal meningoencephalitis in HIV-infected patients in Madagascar
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007984 January 13, 2020 12 / 14
3. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender N P, Chiller TM, et al. Global burden of dis-
ease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017; 17
(8):873–881. https://doi.org/10.1016/S1473-3099(17)30243-8 PMID: 28483415
4. Cogliati M. Global Molecular Epidemiology of Cryptococcus neoformans and Cryptococcus gattii: an
atlas of the molecular types. Scientifica (Cairo). 2013; 2013:675213. https://doi.org/10.1155/2013/
675213 PMID: 24278784
5. Kwon-Chung KJ, Fraser JA, Doering TL, Wang Z, Janbon G, Idnurm A, et al. Cryptococcus neoformans
and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med. 2014;
4(7):a019760. https://doi.org/10.1101/cshperspect.a019760 PMID: 24985132
6. Hagen F, Khayhan K, Theelen B, Kolecka A, Polacheck I, Sionov E, et al. Recognition of seven species
in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol 2015; 78:16–
48. https://doi.org/10.1016/j.fgb.2015.02.009 PMID: 25721988
7. May RC, Stone NR, Wiesner DL, Bicanic T, Nielsen K. Cryptococcus: from environmental saprophyte
to global pathogen. Nat Rev Microbiol. 2016; 14(2):106–117. https://doi.org/10.1038/nrmicro.2015.6
PMID: 26685750
8. Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E, IberoAmerican Cryptococcal Study Group.
Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis. 2003; 9
(2):189–195. https://doi.org/10.3201/eid0902.020246 PMID: 12603989
9. Lin X, Heitman J. The biology of the Cryptococcus neoformans species complex. Annu Rev Microbiol.
2006; 60:69–105. https://doi.org/10.1146/annurev.micro.60.080805.142102 PMID: 16704346
10. Frola C, Guelfand L, Blugerman G, Szyld E, Kaufman S, Cahn P, et al. Prevalence of cryptococcal
infection among advanced HIV patients in Argentina using lateral flow immunoassay. PLoS One. 2017;
12(6):e0178721. https://doi.org/10.1371/journal.pone.0178721 PMID: 28617817
11. Sloan DJ, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options. Clin Epidemiol.
2014; 6:169–182. https://doi.org/10.2147/CLEP.S38850 PMID: 24872723
12. UNAIDS. Country factsheets Madagascar 2017. Available at http://www.unaids.org/fr/regionscountries/
countries/madagascar (accessed 25 March 2019)
13. Hansen J, Slechta ES, Gates-Hollingsworth MA, Neary B, Barker AP, Bauman S, et al. Large-scale
evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of
cryptococcal antigen in serum and cerebrospinal fluid. Clin Vaccine Immunol. 2013; 20(1):52–55.
https://doi.org/10.1128/CVI.00536-12 PMID: 23114703
14. Rouet F, Chaix ML, Nerrienet E, Ngo-Giang-Huong N, Plantier JC, Burgard M, et al. Impact of HIV-1
genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de
Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase
polymerase chain reaction test. J Acquir Immune Defic Syndr. 2007; 45(4):380–388. https://doi.org/10.
1097/QAI.0b013e3180640cf5 PMID: 17468666
15. Ogundeji AO, Albertyn J, Pohl CH, Sebolai OM. Method for identification of Cryptococcus neoformans
and Cryptococcus gattii useful in resource-limited settings. J Clin Pathol. 2016; 69(4):352–357. https://
doi.org/10.1136/jclinpath-2014-202790 PMID: 26598625
16. Irinyi L, Serena C, Garcia-Hermoso D, Arabatzis M, Desnos-Ollivier M, Vu D, et al. International Society
of Human and Animal Mycology (ISHAM)-ITS reference DNA barcoding database—the quality con-
trolled standard tool for routine identification of human and animal pathogenic fungi. Med Mycol. 2015;
53(4):313–337. https://doi.org/10.1093/mmy/myv008 PMID: 25802363
17. Firacative C, Trilles L, Meyer W. MALDI-TOF MS enables the rapid identification of the major molecular
types within the Cryptococcus neoformans/C. gattii species complex. PloS One. 2012; 7(5):e37566.
https://doi.org/10.1371/journal.pone.0037566 PMID: 22666368
18. Esposto MC, Cogliati M, Tortorano AM, Viviani MA. Determination of Cryptococcus neoformans var.
neoformans mating type by multiplex PCR. Clin Microbiol Infect. 2004; 10(12):1092–1094. https://doi.
org/10.1111/j.1469-0691.2004.00972.x PMID: 15606637
19. Cogliati M., Allaria M., Tortorano A.M., Viviani M.A.: Genotyping Cryptococcus neoformans var. neofor-
mans with specific primers designed from PCR-fingerprinting bands sequenced using a modified PCR-
based strategy. Med Mycol. 2000; 38(2):97–103. https://doi.org/10.1080/mmy.38.2.97.103 PMID:
10817225
20. Cogliati M, Andrianarivelo MR, Ellabib M, Nnadi EN, Cornet M. Molecular-type specific multiplex PCR
produces a distinct VNII PCR pattern among Cryptococcus neoformans species complex. Med Mycol.
2019; 57(3):384–386. https://doi.org/10.1093/mmy/myy022 PMID: 29762748
21. Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F, et al. Cryptococcus
neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility end-
point distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob
Agents Chemother. 2012; 56(6):3107–3113. https://doi.org/10.1128/AAC.06252-11 PMID: 22391546
Cryptococcal meningoencephalitis in HIV-infected patients in Madagascar
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007984 January 13, 2020 13 / 14
22. Espinel-Ingroff A, Allern AI, Canton E, Castaño´n-Olivares LR, Chowdhary A, Cordoba S, Cuenca-
Estrella M, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study
of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraco-
nazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 2012; 56(11):5898–5906.
https://doi.org/10.1128/AAC.01115-12 PMID: 22948877
23. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical com-
parison of models that directly estimate the prevalence ratio. BMC Res Methodol 2003; 20:3–21.
https://doi.org/10.1186/1471-2288-3-21
24. Beyene T, Zewde AG, Balcha A, Hirpo B, Yitbarik T, Gebissa T, et al. Inadequacy of high-dose flucona-
zole monotherapy among cerebrospinal fluid cryptococcal antigen (CrAg)-positive human immunodefi-
ciency virus-infected persons in an Ethiopian CrAg screening program. Clin Infect Dis. 2017; 65
(12):2126–2129. https://doi.org/10.1093/cid/cix613 PMID: 29020172
25. Kouakou GA, Ello NF, Kassi NA, Keita M, Doumbia A, Mossou C, et al. [Fluconazole 1200mg or 800mg
for cryptococcal meningitis treatment in Ivory Coast]. J Mycol Med. 2017; 27(1):72–78. https://doi.org/
10.1016/j.mycmed.2016.10.001 PMID: 28108201
26. Wajanga BM, Kalluvya S, Downs JA, Johnson WD, Fitzgerald DW, Peck RN. Universal screening of
Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and
reduce mortality: an operational study. J Int AIDS Soc. 2011; 14:48. https://doi.org/10.1186/1758-2652-
14-48 PMID: 21988905
27. Guidelines for The Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected
Adults, Adolescents and Children: Supplement to the 2016 Consolidated Guidelines on the Use of Anti-
retroviral Drugs for Treating and Preventing HIV Infection. World Health Organization, Geneva (2018)
28. Raberahona M, Rakotoarivelo RA, Randriamampionona N, Rakotomalala AF, Razafinambinintsoa T,
Be´net T, et al. Rapid fatal outcome of cryptococcal meningoencephalitis in a non-HIV immunocompro-
mised patient with a low fluconazole susceptibility isolate: a case report from Madagascar. Case Rep.
Infect. Dis. 2016; 2016:3492504. https://doi.org/10.1155/2016/3492504 PMID: 28078149
29. Aminnejad M, Cogliati M, Duan S, Arabatzis M, Tintelnot K, Castañeda E, et al. Identification and char-
acterization of VNI/VNII and novel VNII/VNIV hybrids and impact of hybridization on virulence and anti-
fungal susceptibility within the C. neoformans/C. gattii species complex. PLoS One. 2016; 11(10):
e0163955. https://doi.org/10.1371/journal.pone.0163955 PMID: 27764108
Cryptococcal meningoencephalitis in HIV-infected patients in Madagascar
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007984 January 13, 2020 14 / 14
